MTEX Mannatech Inc.

Mannatech Secures Exclusive Source of Highest Grade Aloe Product in the World from Natural Aloe Costa Rica

Mannatech®, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced it has entered an exclusive agreement with Natural Aloe Costa Rica, to purchase Manapol® powder, which is the highest quality aloe vera gel extract in the world.

According to Dr. Steve Nugent, Mannatech’s Global Wellness Director and Chairman of Mannatech’s Global Scientific Advisory Board, “No other company, aside from Mannatech, has access to true acemannan as defined by science. Manapol powder supplied from Natural Aloe Costa Rica exceeds what is required to have true acemannan, which has been defined by the Chemical Abstract Service (CAS) as requiring a molecular weight of one to two million Daltons. This is where the potency and power of the aloe vera plant resides.”

Ordinary aloe gel inner leaf powder does not meet the scientific definition of acetylated, mannose-rich polysaccharides, known as acemannan. Acemannan requires an atomic weight of at least 1 million Daltons, and most other aloe products claiming to be acemannan do not meet these requirements. Mannatech’s Manapol powder has a guaranteed molecular weight of more than one million Daltons1, testing higher than any other aloe gel extract, which is what gives it the extraordinary and scientifically documented effects in human studies.

Natural Aloe Costa Rica has worked closely with Mannatech for many years to develop the most potent and pure aloe vera gel extract available. This includes its innovative and proprietary extraction processes that ensure the gel extract is as pure and potent as possible. Additionally, Natural Aloe Costa Rica employs cutting edge farming techniques that produce aloe vera plants that yield a higher volume of aloe gel containing acemannan.

“Through our exclusive partnership and proprietary extraction method with Natural Aloe Costa Rica, Mannatech is well positioned as the global provider of the highest quality, highest potency aloe vera-based products available on the market today,” said Mannatech’s CEO and President, Alfredo “Al” Bala. “Aloe vera is a significant part of Mannatech’s science-backed Glyconutrional technology. This partnership enables Mannatech to continue to harness the power of Glyconutrition to the benefit of our customers globally.”

Manapol powder, which supports optimal cellular communication*, is a pure, premium, 100 percent aloe vera gel extract that is abundant in acemannan, designed to support a healthy immune system.* As the most cutting-edge Glyconutritional product available, Manapol powder additionally may provide gastrointestinal benefits.*

For more than 20 years, Manapol powder has been an essential ingredient in other Mannatech products. Mannatech’s Advanced Ambrotose® product and Ambrotose® complex are among the company’s top-selling products containing the aloe gel extract, and are known for their cognitive, immune and gastrointestinal benefits.*

Mannatech’s technology has been the subject of numerous clinical tests. Currently, 19 studies have been published in peer-reviewed journals, 17 human clinical trials have been published and 12 of those studies were double-blind, placebo-controlled studies — the gold standard for product validation. To date, Mannatech has obtained 125 patents in major global markets to help protect its products and formulas, separating it from other nutritional supplement and direct selling companies. Mannatech’s products and formulations are manufactured under the strictest quality controls, with many of Mannatech’s core products certified by NSF International.

To begin changing your life or the lives of those around you, please visit Mannatech.com.

1 Chemical Abstract Service (CAS) has defined acemannan as requiring a molecular weight of one to two million Daltons.

About Mannatech

Mannatech, Incorporated, offers a profound wellness experience through a financially rewarding opportunity that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in 25 countries, Mannatech is committed to changing lives. For more information, visit Mannatech.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

EN
01/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mannatech Inc.

 PRESS RELEASE

Mannatech Reports Financial Results for Third Quarter 2025

Mannatech Reports Financial Results for Third Quarter 2025 FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net s...

 PRESS RELEASE

Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of ...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the “Board”) appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominat...

 PRESS RELEASE

Mannatech Reports Financial Results for Third Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease...

 PRESS RELEASE

Mannatech Reports Financial Results for Second Quarter 2024

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease ...

 PRESS RELEASE

Mannatech Announces Appointment of James Clavijo as Chief Financial Of...

FLOWER MOUND, Texas--(BUSINESS WIRE)-- (NASDAQ: ) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ: LVGN), Guided Therapeutics (OTC: GTHP), Aeterna Zentaris (NASDAQ: AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch